Fierce Names Rallybio to 2024 Fierce 50 List as an Innovation Honoree Page 1

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Fierce Life Sciences and Fierce Healthcare have named Rallybio an Innovation Honoree to the 2024 Fierce 50 list. The Fierce 50 recognizes 50 individuals and companies that are driving advances in medicine, advancing innovation, and shaping the future of biopharma and healthcare.

“The annual Fierce 50 special report highlights individuals and companies making progress in the pharmaceutical, healthcare and biotechnology industries,” said Ayla Ellison, editor-in-chief of Fierce Life Sciences and Healthcare. “These 50 outstanding organizations and people demonstrate excellence in their fields, and their dedication to innovation, equality and improving lives is truly commendable. Congratulations to this year’s honorees.”